Augmented Bone Graft Market Size, Share Analysis, Strategies, Revenue And Forecasts To 2023

 According to the British Editorial Society of Bone & Joint Surgery, bone is the second most common transplanted tissue after blood with an estimated 2.2 million grafting procedures worldwide annually as recorded in 2015. This development has been fuelled by the increasing cases of fractures and accidents around the world.

The Global Augmented Bone Graft Market is expected to grow at a CAGR of approximately 7.8% during the forecast period 2017-2023.

Augment Bone Graft is a combination drug/device product used for repairing the bone and reviving its regenerative properties. It is used as an alternative to autograft in arthrodesis of the ankle or hindfoot indicating the need for supplemental graft material. The use of augment bone graft eliminates the need for a second surgery to harvest autologous bone, thereby avoiding donor site morbidity. According to the National Health Interview Survey, in 2012, around 126 million adults were affected by this disease in the U.S. According to the Labor Force Survey (LFS), about 553,000 cases were registered for all work-related musculoskeletal disorder out of the total of 1,243,000 cases.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/4961

Allografts and bovine-derived bone graft products dominate the augmented bone graft market. These materials have variations in particle size which is their main drawback. The recent technological trend is to replace these natural materials with alloplastic bone grafts such as ceramics and polymers as they can be manufactured to the precise size and characteristics.

There has been increasing acceptance of bone grafting procedures which drives the market for augmented bone graft products. Many healthcare professionals have started using these bone grafts, especially in tertiary care centers and specialty hospitals which may promote and increase the demand for augmented bone graft. These bone graft works in a unique way to stimulate three key processes of early bone healing.

Various other factors such as, increasing advancement in technology, and rising adoption rate of new technology continuously contribute to the growth of this market. Despite these developments, high cost of surgeries and ethical issues related with bone grafting procedures may hamper the growth of the market. For instance, a study conducted by BMC Medical Ethics states that in a sample of 100 patients, about 20% of the patients refuse to accept allografts for their grafting surgery.

Additionally, stringent regulations obstruct the growth of augmented bone grafts market size and inadequate reimbursement policies for bone grafting also hampers the growth of global bone grafts market. Rapid product launches and increasing mergers and acquisitions between bone graft systems manufacturing companies are some of the major trends in the global bone grafts market.

The Key Players

• Zimmer Holdings, Inc.
• BioMimetic Therapeutics LLC
• Wright Medical Technology, Inc.
• Stryker Corporation, Smith & Nephew Plc
• RTI Surgical, Inc.,
• Olympus Biotech Corporation
• NuVasive, Inc.
• NovaBone Products LLC
• Medtronic, Inc.
• LifeNet Health, Inc.
• Integra LifeSciences Holdings Corporation
• Exactech, Inc.
• DePuy Spine, Inc.
• Synthes Inc.
• DePuy Synthes Companies
• Biomet, Inc.

Segmentation

The Augmented Bone Graft is segmented on the basis of products, application, and end-users.

On the basis of application, the market is segmented into the Craniomaxillofacial, Dental, Foot & Ankle, Joint Reconstruction, Long Bone, and Spinal Fusion

On the basis of product, the market is segmented into the Allografts, Bone Grafts Substitutes, and Cell-based Matrices. The Allografts segment is further sub divided into Machined Allografts and Demineralized Bone Matrix. The Bone Grafts Substitutes is also sub categorized as Bone Morphogenic Proteins (BMP) and Synthetic Bone Grafts.

On the basis of end-user, the market is segmented into hospitals, clinics, ambulatory surgical centers and others.

Regional Analysis

The Global Augmented Bone Graft Market consists of countries namely America, Europe, Asia Pacific, and the Middle East.

North America dominated the global augmented bone graft market owing to the increasing healthcare expenditure in North America since 2016. Canadian healthcare specifically was stressed by an advancing demographic move. The increase of insurance coverage because of health care reform (Affordable Care Act) in the United States additionally prompted an expansion in health care spending. In 2016, healthcare organizations found liberation from a special tax on medical devices (Medical Device Excise Tax). The United States Congress put off the tax for a long two years in 2015.

For Europe, the healthcare spending has expanded slightly in Germany. Neverthelss, the orthopedic biologics market including the bone graft substitute market has been determined by solid strong competition and price pressure. While volume of sales and the scope of new treatment techniques are on the ascent, net revenues in the German market are declining. Western Europe continues to see a need to save money on healthcare because of a slight drop in financial growth and obstinate economic pressure.

Healthcare spending in Asia expanded in 2016 due to an extension of state health care programs and the increasing affluence of the population. India, in specific, saw an expansion in spending due to a government resolution to enhance healthcare services.

Furthermore in the Middle East & Africa the spending for healthcare was also increased. This was essentially because of elections in a few nations, (for example, Ghana, Niger, Uganda, Zambia and Somalia), healthcare growth and population growth. Awareness for medicinal technology likewise expanded extraordinarily. Due to of low local production, the region is dependent on imported medicinal products. The import standard in numerous nations is 80% to 90%.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/augmented-bone-graft-market-4961

Acute Care Electronic Health Recorder (EHR) Industry Growth, Trends And Forecast Till 2023 By Marketresearchfuture.Com

 Acute care EHR is different from its traditional counterparts. The acute care EHR allows healthcare professionals to collect, preserve and access vital patient clinical data in acute care and ambulatory care settings. Market Research Future (MRFR) perceives the global acute care EHR market to register a CAGR of 7% over the forecast period of 2017-2023.

The global acute care EHR market driven by the surging incidences of chronic diseases on a global scale. In recent years, the prevalence of chronic diseases such as cancer, diabetes, and cardiovascular disease have been on the rise which has consequently raised the number of healthcare institutions. Growth in a number of hospitals and other medical centers have created massive demand for management of patient data which boosts the growth of the global acute care EHR market. The rise in global geriatric population is also a contributing factor to the growth of the global acute care EHR market. The aged population who are more susceptible to suffer from chronic diseases have induced high demand for remote monitoring of geriatric patient data. Factors such as development in healthcare IT, technological advancements and expanding expenditure on healthcare act as a plus for the growth of the market. On the contrary, the growth of the global acute care EHR market might be restrained by high costs associated with acute care EHR solutions which might limit the growth of the market in price-sensitive market. Furthermore, towering costs of healthcare devices and treatments are also likely to hinder market growth.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/4930

Competitive Landscape

The noteworthy players in the global acute care EHR market include Epic Systems Corporation (U.S.), Evident (CPSI) (U.S.), eClinicalWorks (U.S.), Medhost (U.S.), Athenahealth (RazorInsights) (U.S.), IBM (U.S.), Vitera Healthcare Solutions (U.S.), Meditech (U.S.), McKesson Corporation (U.S.), Allscript (U.S.), Cerner Corporation (Siemens) (U.S.), Healthland (U.S.), and General Electric Company (U.S.).

Segmentation

The global acute care EHR market has been segmented based on deployment, application, and end user.

By deployment, the global acute care EHR market has been segmented into On-Premises based and Web-based.

By application, the global acute care EHR market has been segmented into personal care, pharmaceuticals, and others.

By end user, the global acute care EHR market has been segmented into hospital, ambulatory care, and others.

Regional Analysis

The Americas dominate the global acute care EHR market owing to the increasing number of hospitals ambulatory centers, presence of huge patient population and well developed technology. The hospital and clinics are able to afford the cost of the devices as these are funded by several sources: the public sector, charities, health insurance companies, health organizations of all kinds, etc. Additionally, the people in this region are able to afford high cost of treatment on account of higher per capita income in this region. Rapidly increasing patient population, governments have started supporting the manufacturers for the development of new and better devices which has driven the growth of the market. Moreover, well developed technology, high healthcare expenditure, and huge geriatric population have fuelled the growth of the market in this region.

Asia Pacific is the fastest growing acute care EHR market owing to the increasing number of patients suffering from chronic diseases and rapidly increasing number of hospitals & clinics. Additionally, rapidly growing economies and increasing healthcare expenditure will fuel the growth of the market. On the other hand, the Middle East & Africa hold the least share of the market owing to less availability of funds, limited availability of medical facilities, and poor political conditions in Africa.

Europe commands the second largest market for acute care EHR which is followed by Asia Pacific. Availability of funds, strong government support, and increasing need for the better management devices & platform drive the growth of the market in Europe. Western Europe holds a major share of the market due to the presence of well developed economies. U.K, Germany and France are the major contributors of the market.

Industry Updates

• In November 2018, ResMed, a company that specializes in connected devices and remote monitoring for sleep apnea and respiratory illnesses announced the acquisition of MatrixCare’s post-acute care EHR solution for USD 750 million.

 

• In December 2018, Allscripts, a provider of healthcare solutions, announced selling of its stake in post-acute care EHR vendor Netsmart to TA Associates and GI Partners, both private equity firms for a total amount of USD 525 million.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/acute-care-ehr-market-4930 

Retropharyngeal abscess Market Up To 2023: Top Companies, Growth Factors Details And Regional Overview By Types & Application

 Market scenario:

Retropharyngeal abscess is a serious infection deep in the neck and generally occurs in children under age eight, though it can also affect adults. The symptoms include difficulty in breathing and swallowing, pain, severe cough and throat pain, neck stiffness and spasms and others. If left untreated, retropharyngeal abscess infection can result in septic shock, organ failure and death. Retropharyngeal abscess recurs in an estimated 1 to 5% of patients and such patients are 40 to 50% more likely to die due to abscess-related complications.

 

The Latest report by Market Research Future (MRFR) asserts that, The global retropharyngeal abscess market is expected to reach USD 5.9 billion by 2023, and the market is projected to grow at a CAGR of ~ 4.5 % during the forecast period 2017-2023.

 

The market drivers include rise in demand due to growing young and immune-compromised population, increasing screening, and others. The market restraints are the complications such as risk of bleeding, pain, especially during surgery, high cost of treatment, poor healthcare penetration and others.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/4922

 

Development of antibiotics resistant bacteria is the single most unmet need of the market. Product development represents the best strategy for the market growth. The market is expected to witness exponential growth over the review period owing to development of selective gram negative antibiotics. Market development is another strategy for as there is a large unmet need in the developing regions such as India and China. Cost of the product will be a decisive factor in the developing regions such as Asia Pacific and especially Africa.

Key Players

• Merck KGaA,
• Johnson & Johnson,
• AstraZeneca plc,
• Sanofi S.A.,
• Pfizer,
• Mylan N.V,
• Novartis AG,
• Teva pharmaceutical company,
• GlaxoSmithKline plc.

Segments

The global retropharyngeal abscess market has been segmented on the basis of diagnosis, treatment, and end user.

Based on the diagnosis, the market has been segmented as X-rays and computed tomography, blood tests, physical exam and others.

Based on the treatment, the market has been segmented as calcium antibiotics, pain killers, surgical drainage and others.

Based on the end user, the market has been segmented as hospitals and clinics, research and academics and others.

Regional Analysis

Asia Pacific retropharyngeal abscess market size is expected to grow rapidly; China and India are likely to lead this market due to fast growing healthcare sector and large unmet needs over the forecast period. South East Asian countries such as China, India, and Malaysia are projected to contribute highly to the market growth. The growing penetration of healthcare industry in the Asia Pacific region is expected to drive the future retropharyngeal abscess market in the region. However the low expenditure on healthcare coupled with the poor incomes in the developing regions is a dent on the market.

A significant market share of the global retropharyngeal abscess market is held by the Americas, owing to high expenditure on the health care especially in major countries of the region like the U.S. and Canada. Additionally, the number of cardiac procedures in the U.S and Canada is increasing due to greater healthcare penetration, which drives the retropharyngeal abscess market. The high concentration of the major hospitals in the developed countries of this region coupled with good reimbursement rates is adding fuel to the market growth. Moreover, the large share of infective procedures treatment in the returns of hospitals favors the market. The large number of pharmaceutical companies in the U.S. is also a cause for the faster development of retropharyngeal abscess market in the US. The development of broad spectrum antibiotics in developed regions such as the U.S. and Europe is a strong driver of the market.

Europe is the second largest market in the world due to growing pharmaceutical industry and healthcare penetration. The European market growth is led by countries such as Germany and France. Germany is expected to be the fastest growing market over the assessment period due to its large pharmaceutical and microsurgery devices industry. The development of Methicillin-resistant Staphylococcus aureus (MRSA) especially in the southern regions of Europe such as Spain, Italy etc. stimulates the market.

Gulf nations such as Saudi Arabia and the UAE are estimated to drive the Middle East & African market. Other Middle East nations to watch out for are Kuwait, Jordan, Egypt and Iran. The African region is expected to witness a poor growth owing to poor economic and political conditions, and poor healthcare development. Other regions are expected to be laggards due to poor social development and tribal identities such as sub Saharan Africa.

Access More Details of the Report @ https://www.marketresearchfuture.com/reports/retropharyngeal-abscess-market-4922

Encephalomyelitis Market Professional Overview 2019-2023 With Major Vendors Size, Shares And Worldwide Demand

 Market Scenario

Encephalomyelitis is brain or spinal cord inflammation caused due to virus, infections, and other foreign particles. The patient suffering from autoimmune diseases and AIDS are more prone to the diseases. A wide range of drugs are available for the treatment of this disease, however no precise treatment is available to cure the disease. Increasing prevalence of encephalomyelitis and autoimmune diseases has boosted the growth of the market. According to the WHO, 4.3 million people across the globe are affected by this disease. Additionally, changing lifestyle, increasing geriatric population, increasing need for better treatment has driven the global market. Moreover, increasing government support along with the per capita income have fuelled the market growth. However, limited and high cost of treatment options may retard the growth of the market over the assessment period.

The global encephalomyelitis market is expected to grow at a CAGR of ~8.1 % during the forecast period 2017-2023. 

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/4874

Segmentations

The global encephalomyelitis market is segmented on the basis of types, treatment and end users.

On the basis of treatment, the market is segmented into drug treatment, plasmapheresis, surgery, and others. Drug therapy is further segmented into antiviral medications, antibiotics, steroids, sedatives, NSAIDs, mood stabilizers, and others.

On the basis of types, the market is segmented into acute disseminated encephalomyelitis, encephalomyelitis disseminata, antiMOG associated encephalomyelitis, equine encephalomyelitis, AIDS related encephalomyelitis and others.

On the basis of end users, the market is segmented into hospital, clinics and others.

Regional Analysis

The Americas command a major of the Encephalomyelitis market share owing to the large patient population, growing prevalence of encephalomyelitis & autoimmune diseases, and strong government support for research & development. According to the American Autoimmune Related Diseases Association, approximately 50 million people in the U.S. were reported to be suffering from autoimmune diseases in 2014.

Europe accounts for the second largest market across the globe, which is followed by Asia Pacific. Strong government support, availability of funds for research and high healthcare expenditure drives the growth of the market. Asia Pacific is the fastest growing market. China, and India are the key contributors to the market growth due to presence of huge population base, increasing prevalence of AIDS and autoimmune diseases, rapidly growing economy, and increasing healthcare expenditure. Additionally, increasing government support, and presence of huge opportunity have fuelled the growth of the market in Asia Pacific.

The Middle East & Africa holds the least share of the global market due to limited availability of medical facilities and poor economic condition in African region. The UAE, Saudi Arabia, and Kuwait are expected to drive the Middle East & African market owing to the well-developed economy and high healthcare spending.

Key Players

Some of key the players in the market are Bristol-Myers Squibb Company (U.S.), Sanofi (France), GlaxoSmithKline Plc. (U.K), Spectrum Pharmaceuticals Inc. (U.S.), Amgen, Inc. (U.S.), Merck & Co., Inc. (U.S.), Bayer AG (Germany), Novartis AG (Switzerland), F. Hoffmann-La Roche Ltd. (Switzerland), Eli Lilly and Company (U.S.), AstraZeneca Plc. (U.K), Janssen Biotech, Inc. (U.S.), AbbVie Inc. (U.S.), Takeda Pharmaceuticals (Japan), Immunomedics (U.S.), Pfizer, Inc. (U.S.), and Oncomed Pharmaceuticals (U.S.).

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/encephalomyelitis-market-4874

Genetic Testing Market Likely Boost The Industry Revenue And Demand Till 2023

  Market Research Future With Their Unique Quality Of Simplifying The Market Research Study, Announces A Deep Study Report On “Genetic Testing Market Research Report – Forecast To 2023” Gives Industry Size, Top Players And Worldwide Demand

Genetic Testing Market overview  

Genetic testing is a process that involves a set of lab tests for the study of the genetic makeup of the patient and identifying the gene mutations and alterations in the healthy structure of the DNA that leads to the development of the genetic disorders. The genetic tests help to confirm and rule out the suspected genetic condition and it also helps to determine the probability of developing a genetic disorder or for passing the same to the next generation.  

Also Read :  https://www.marketwatch.com/press-release/coronavirus-covid-19-impact-on-genetic-testing-market-2020-global-analysis-development-pipeline-regional-outlook-top-company-profile-size-estimation-global-share-2020-06-24 

There have been more than 1,000 genetic tests that are in use and for more that are being developed. The genetic testing helps in studying the gene that is present in cells and tissues. The genetic disorders such as sickle cell anemia, cancer, cystic fibrosis, Down syndrome, and others. There are different techniques that are used for employing the gene tests for producing kits, media, reagents and others.   

The global genetic testing market report presents the benefits of genetic testing, the rising prevalence of genetic disorders, and the changing trends that range from service-driver to product-driven industry. The genetic testing market is anticipated to grow at the CAGR of 11.50% and it will reach USD 22, 834.19 million by the year 2024. But the high cost of tests and the inaccuracy of tests will be a threat for the growth of the global genetic testing market.  

 

Genetic Testing Market Key Players

The major players in the global market are Myriad Genetics, Inc. (US), PerkinElmer Inc. (US), Abbott Laboratories (US), Bio-Rad Laboratories, Inc. (US), Illumina Inc. (US), QIAGEN (Germany), Quest Diagnostics Incorporated (US), Eurofins Scientific (US), F. Hoffmann-La Roche Ltd (Switzerland), Blueprint Genetics (Finland), Thermo Fisher Scientific Inc. (US), and BGI Genomics (China).

Genetic Testing Market segmentation 

The genetic testing market report presents the growth of the global market with the rise in the growth of genetic testing. On the basis of method, the global genetic testing can be split into: 

• Chromosomal genetic tests
• Molecular genetic tests/DNA tests
• Biochemical tests
• Genetic tests 

And on based on the type, the global genetic testing market can be classified into: 

 

• Direct to consumer genetic testing
• Prescribed genetic testing 

And based on the applications, the global market can be differentiated as: 

• Cancer screening
• Reproductive health
• Predictive and presymptomatic testing
• Ancestry
• Others 

The reproductive health segment presents the market value of USD 3,993.67 million in 2018. 

Genetic Testing Market Regional analysis  

The genetic testing market comprises the growth of the global market that is based on the regions of Asia-Pacific, Europe, Americans, Middle East and Africa. The American region dominated the global market based on the increasing genetic diseases and abnormalities. The government supports research and development in genetics that are the major driving factors for the growth of the global market. The European market is used for genetic testing and that is the second-largest during the forecast period. There is a presence of genetic diseases and disorders that has expanded the scope of the development of different genetic tests. The market in Japan holds the market share of 27.7% in the year 2018.  

Genetic Testing Industry news  

Bio-Rad Laboratories, a global leader of life science research products, has announced that the company will be launching a blood-based immunoassay kit for identifying antibiotics for the COVID-19. The performance of the assay has been established for undergoing clinical evaluation in different hospitals for further clinical performance.

FOR MORE DETAILS - https://www.marketresearchfuture.com/reports/genetic-testing-market-2009

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

 

Worldwide Herbal Medicine Market 2019 Synopsis With Leading Players, Industry Growth Factor Foresight By 2023

  Market Research Future With Their Unique Quality Of Simplifying The Market Research Study, Announces A Deep Study Report On “Herbal Medicine Market Research Report – Forecast To 2023” Gives Industry Size, Top Players And Worldwide Demand

Global Herbal Medicine Market Size is expected to reach a valuation of more than USD 129 billion by 2023, according to the latest research report from Market Research Future (MRFR). The market is expected to exhibit a strong 5.88% CAGR over the forecast period from 2018 to 2023, according to the report.

Market Overview

Herbal medicine comprises products derived from plants and consumed directly with little processing. The lack of extensive processing is probably the major difference between herbal medicine and conventional medicine, as the field of herbal medicine seeks to preserve the natural composition of the plant, while conventional medicine devotes considerable efforts to isolate the active ingredient and produce it on a large scale into medicinal products. This field of medicine has been the oldest field of medicine in human history, as all medicine originally started with the use of plant materials for remedial action against various natural ailments. The field has experienced a resurgence in recent years due to the growing demand among consumers for naturally oriented, process-free, chemical-free medicine. Preference for personal medication could also drive the global herbal medicine market at a strong rate over the forecast period.

Also Read : https://www.globenewswire.com/news-release/2019/04/03/1796359/0/en/Herbal-Medicine-Market-Value-to-Surpass-USD-129-Billion-Revenue-Mark-by-2023-at-5-88-CAGR-Predicts-Market-Research-Future.html 

Competitive Analysis

Leading players in the global herbal medicine market include Arkopharma, Beovita, Schaper & Brummer, Venus Pharma GmbH, Arizona Natural Products, Dasherb Corp., ZeinPharma Germany GmbH, Hishimo Pharmaceuticals, and Bayer AG.

Segmentation

By category, the global herbal medicine market is segmented into herbal pharmaceuticals, herbal functional foods, herbal dietary supplements, and herbal beauty products. Herbal pharmaceuticals are by far the most dominant product segment in the global herbal medicine market and accounted for a valuation of more than USD 50.9 billion in 2017.

By type of medicinal plant, the global herbal medicine market is segmented into Marrubium vulgare, Cinnamomum spp., Vaccinium macrocarpon, Echinacea, Camellia sinensis, Curcuma longa, Actaea racemosa, Aloe vera, Zingiber officinale, Cocos nucifera, and others. Marrubium vulgare, commonly known as the white horehound, is likely to dominate the global herbal medicine market over the forecast period with a CAGR of 6.45%.

By form, the market is segmented into capsules and tablets, powders, extracts, syrups, and others. Extracts account for the largest market share in 2017 and are likely to remain dominant over the forecast period.

By source, the global herbal medicine market is segmented into leaves, roots and barks, fruits, whole plants, and others. The leaves segment is likely to lead the global herbal medicine market over the forecast period.

By distribution channel, the market is dominated by hospitals and retail pharmacies, which accounted for 55.82% of the global market in 2017, followed by ecommerce and others.

Growing Demand for Natural Medicines

While conventional medicine has worked tirelessly to produce harmless, isolated products from plants, the commercial aspect of conventional medicine has annoyed many consumers, while the increasing use of synthetic chemicals in medicine has also irked off a significant population. These consumers are increasingly demanding all-natural alternatives to conventional medicine, which has driven the demand for herbal medicine across the world, including developed regions such as North America and Europe as well as developing countries in Asia Pacific, Latin America, and the Middle East and Africa. The increasing number of consumers opting for natural alternatives to conventional medicine is likely to remain the strongest driver for the global herbal medicine market over the forecast period.

Growing Clinical Research into Perfecting Herbal Medicine

Governments in developed countries, especially in Europe, have also been quick to take into account the growing demand for herbal medicine and have funded significant research efforts into the field to enhance the precision and sophistication of the field. This is likely to be a major driver for the Herbal Medicine Market over the forecast period, as government-funded clinical research facilities could provide a sophisticated, polished version of herbal medicine, providing the customer with the best of both worlds.

Regional Analysis

Europe is likely to remain the major regional market for herbal medicine over the forecast period due to the strong government support to clinical research into improving herbal medicine and the growing consumer demand for natural variants to conventional medicine. Asia Pacific is also likely to play a major role in the growth of the global herbal medicine market over the forecast period due to the traditional use of herbal medicine in many parts of the region.

Lack of Standardization to Hamper Herbal Medicine Market

One of the most pressing concerns for the Herbal Medicine Market is a lack of standardization among global entities and the consequent confusion and decline in trust among consumers. Due to the use of traditional methods to prepare herbal medicine in various regions, global outreach has been difficult to achieve, as different locales may prepare the same medicine in a different way. This has the potential to stunt the global herbal medicine market’s growth over the forecast period, as the well-established distribution channels of conventional medicine could give it a strong advantage over the former in the coming years.

The higher risk of allergies and other adverse effects through the use of herbal medicine is also a major restraint against the global herbal medicine market. Due to the absence of the processes practiced in conventional medicine production to remove all possible threats from the plant material and isolate only the clinically active ingredient, herbal medicine poses a greater overall risk of side effects or allergies and other harmful reactions to the medicine. This is likely to remain a key concern for the market till a strong level of standardization is achieved in herbal medicine products.

FOR MORE DETAILS- https://www.marketresearchfuture.com/reports/herbal-medicine-market-3250

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

 

Anti-viral Drugs Market Report By Global Industry Trends And Forecast The Upcoming Opportunities And Demand Till 2023

  Market Research Future With Their Unique Quality Of Simplifying The Market Research Study, Announces A Deep Study Report On “Anti-viral Drugs Market Research Report – Forecast To 2023” Gives Industry Size, Top Players And Worldwide Demand

Market Overview

The rising cases of viral disease is identified to boost the global anti-viral drugs market growth. The inadequacy of dietary nutrition in people, due to increase in consumption of high calorie and low fibrous food is creating favourable condition for virus to invade human body. Hence, the need for anti-viral drugs are surging as viral infections prevail. The growing incidences of HIV and other sexually-transmitted diseases are also boosting the sales number of anti-viral drugs, hence, anticipated to prompt the anti-viral drug market growth.

The increase in cases of drug resistance is propelling extensive research and developmental undertakings for launching more effective anti-viral drugs. Additionally, the stringency in drug approval stages are taking care of the quality of drugs in the pipeline. New product launches are gaining traction for revenue generation for the anti-viral drugs market. The application of anti-viral drugs in other diseases like, bird flu, and others is also likely to prompt the global anti-viral drug growth.

Also Read : https://www.globenewswire.com/news-release/2019/07/26/1892344/0/en/Anti-viral-Drugs-Market-Size-Estimated-to-Upsurge-at-6-9-CAGR-to-Reach-a-Valuation-of-USD-62-67-Billion-by-2022-States-Market-Research-Future.html 

The expiry of patents for certain blockbuster anti-viral drug are stimulating generic drug competition in the anti-viral drug market. This is deepening the competitive scenario of the global anti-viral drug market over the assessment period.

However, adverse effects of anti-viral drugs and high price of anti-viral drugs can hinder the anti-viral drugs market growth over the assessment period.

Competitive Analysis

MRFR have enlisted some of the prominent companies operating in the anti-viral drugs market. They are; Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co. Inc., Gilead Sciences Inc., Cipla Inc. GlaxoSmithKline Plc, Novartis International AG, Abbott Laboratories, and  Astra Zeneca AB. 

Segmentation

The global anti-viral drugs market study has been segmented on the basis of application and mechanism of action.

Based on the application, the anti-viral drugs market has been segmented into Influenza, Hepatitis, Herpes, HIV/AIDS, and others.

Based on the mechanism of action, the anti-viral drugs market has been segmented into Protease Inhibitors, Nucleotide Polymerase Inhibitors, Reverse Transcriptase Inhibitors, and others.

Regional Analysis

Based on the region, the anti-viral drug market has been studied across the Americas, Asia Pacific, Europe, and the Middle East Asia.

MRFR forecasts that the anti-viral drug market in the American region is likely to hold the largest market share. The need for effective treatment of diseases due to the growing cases of viral infection in the region can bolster the anti-viral drugs market. The North American market is expected to grasp greater than 30% of the global market share. The anti-viral drugs market in Europe is likely to garner an impressive CAGR by 2022. MRFR report states that the anti-viral drugs market in Europe will hold the second largest market share over the review period. The anti-viral drug market in the Asia pacific region anticipated to register the highest CAGR over the forecast period. The anti-viral drug market in the Middle East Asia and Africa is expected to exhibit a sluggish growth.

FOR MORE DETAILS - https://www.marketresearchfuture.com/reports/anti-viral-drugs-market-2454

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com